Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bimekizumab OLE in Chronic Plaque Psoriasis
NCT03230292Phase 2Completed
- Sponsor
- UCB
- Start
- Jul 2017
- Primary completion
- Mar 2019
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 2 trial of bimekizumab in psoriasis, sponsored by UCB. Started Jul 2017; status: completed.
02
Drugs
bimekizumab
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT03230292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03230292.